Market Overview

Geron Shares Rally Following Positive Results from Phase 2 Study of Imetelstat

Related GERN
Mallinckrodt Initiates Amyotrophic Lateral Sclerosis Study
Omeros (OMER) Hits New 52-Week High on Positive FDA Decision

Geron Corporation (Nasdaq: GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company's first-in-class telomerase inhibitor, in patients with essential thrombocythemia (ET). ET is a chronic blood disorder that is representative of a group of diseases known as myeloproliferative neoplasms (MPNs). The data, which showed rapid and durable hematologic and molecular responses in patients treated with imetelstat, were presented Sunday evening in an oral session at the 54^th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA, by Prof. Dr. med. Gabriela M. Baerlocher of the University Hospital and University of Bern, Switzerland, and a principal investigator of the trial. To view the presentation slides, please visit

Posted-In: News FDA Movers


Related Articles (GERN)

View Comments and Join the Discussion!